July 15, 2008 -- MedX Health Corp. (Mississauga, Ontario, Canada) (TSXV: MDX) has announced an exclusive distribution agreement with Technology4Medicine, a newly formed laser company based in San Clemente, CA, for the U.S. dental, dermatology, plastic surgery and anti-aging markets. Technology4Medicine will sell MedX Health's newest laser product, Oralase immediately upon clearances from the U.S. Food and Drug Administration to dental offices. Oralase is a low level laser therapy (LLLT) designed for dentists to alleviate pain and accelerate tissue repair following dental procedures.
"This partnership fulfills a key component of our vision for growth," said MedX president and CEO Steve Guillen, who explained that his company aims to become the worldwide leader in light technology. "MedX is committed to choosing the right partners to accelerate product distribution while continuing to develop superior products and explore new therapeutic opportunities," he said.
Last month, MedX filed an application with the U.S. Patent Office for its Photobandage, a bandage technology designed to enhance the healing process by bathing the area surrounding a wound in light.
MedX has given Technology4Medicine exclusive U.S. rights to sell Oralase and other MedX lasers applicable in the dental, dermatology, plastic surgery and anti-aging markets; MedX will continue direct distribution for the U.S. rehabilitation market. Increased levels of promotion are expected to cross over into these other large growth markets.
"This agreement helps put Technology4Medicine on the forefront of laser product distribution," stated Jeff Jones, CEO of Technology4Medicine. "This is a very impressive technology that will further establish our company in the dental industry with the best technology available.
Oralase is an ergonomically designed portable low level laser device that offers dental staff a proven, drug-free solution to eliminate pain and accelerate soft and hard tissue repair. Oralase is designed to effectively control pain and decrease swelling from invasive dental procedures as well as stimulate healing. MedX has submitted to the FDA for marketing approval.